Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer

Purpose Trastuzumab improves survival in patients with HER2+ early breast cancer. However, cardiotoxicity remains a concern, particularly in the curative setting, and there are limited data on its incidence outside of clinical trials. We retrospectively evaluated the cardiotoxicity rates [left ventr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2021-07, Vol.188 (1), p.149-163
Hauptverfasser:	Battisti, Nicolò Matteo Luca, Andres, Maria Sol, Lee, Karla A., Ramalingam, Sivatharshini, Nash, Tamsin, Mappouridou, Stephanie, Senthivel, Nishanthi, Asavisanu, Kalaprapa, Obeid, Mariam, Tripodaki, Elli-Sophia, Angelis, Vasileios, Fleming, Emily, Goode, Emily F., John, Susan, Rosen, Stuart D., Allen, Mark, Stanway, Susannah, Lyon, Alexander R., Ring, Alistair
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anthracycline Breast cancer Breast Neoplasms - drug therapy Cancer research Cardiotoxicity Cardiovascular diseases Clinical Trial Clinical trials Congestive heart failure Demography ErbB-2 protein Female Heart failure Heart Failure - chemically induced Humans Incidence Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Oncology Receptor, ErbB-2 Retrospective Studies Risk Assessment Stroke Volume Targeted cancer therapy Trastuzumab Trastuzumab - adverse effects Trastuzumab - therapeutic use Ventricle Ventricular Function, Left Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!